RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
EyeGate Pharmaceuticals Stock

EyeGate Pharmaceuticals Equity 2024

EyeGate Pharmaceuticals Equity

0 USD

Ticker

EYEG

ISIN

US30233M5031

WKN

A2PRBT

In 2024, EyeGate Pharmaceuticals's equity was 0 USD, a 0% increase from the 0 USD equity in the previous year.

EyeGate Pharmaceuticals Aktienanalyse

What does EyeGate Pharmaceuticals do?

EyeGate Pharmaceuticals Inc. is a US pharmaceutical company specializing in the development of ophthalmology products. It was founded in 1998 and is headquartered in Waltham, Massachusetts. The company aims to meet the need for safe and effective therapies for the treatment of eye diseases. Its business model focuses on the development and commercialization of products that enable faster and more effective treatment of eye diseases. The company has two main divisions. The first division includes iontophoretic drug delivery technologies used for the treatment of eye diseases. Iontophoresis is a process in which electric currents are used to transport medications through the skin and into the eyes. EyeGate Pharmaceuticals has developed the EyeGate® II Delivery System technology, which allows for non-invasive, painless, and safe administration of medications into the eye. The EyeGate II Delivery System can be used for the treatment of inflammation, pain, and infections in the eye area. The second division is the development of drugs used for the treatment of eye diseases. EyeGate Pharmaceuticals has several clinical programs in development, including EGP-437, a steroid-free corticosteroid used for the treatment of inflammation of the anterior eye segment. EGP-437 is currently being tested in two clinical trials to demonstrate its efficacy and safety in the treatment of pain and inflammation in the eye. In addition, the company has developed the drug EGP-259 for the treatment of dry eye. EyeGate Pharmaceuticals has previously entered into several partnerships with other companies to further develop and commercialize its technology platform. In 2019, the company entered into a partnership with Valeant Pharmaceuticals International, Inc. to advance the marketing of EGP-437 in the United States. EyeGate Pharmaceuticals aims to continue growing and expanding its presence in the field of ophthalmology in the coming years. The company is working on the development of new products and technologies that enable it to respond to the changing needs and challenges in ophthalmology. Overall, EyeGate Pharmaceuticals is committed to developing and marketing innovative and effective technologies and drugs for the treatment of eye diseases. The company is well positioned to grow in a rapidly evolving market and make a significant contribution to improving the health and quality of life of millions of people worldwide. EyeGate Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing EyeGate Pharmaceuticals's Equity

EyeGate Pharmaceuticals's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding EyeGate Pharmaceuticals's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating EyeGate Pharmaceuticals's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

EyeGate Pharmaceuticals's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in EyeGate Pharmaceuticals’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about EyeGate Pharmaceuticals stock

What is the equity of EyeGate Pharmaceuticals this year?

EyeGate Pharmaceuticals has equity of 0 USD this year.

What was the equity of EyeGate Pharmaceuticals compared to the previous year?

The equity of EyeGate Pharmaceuticals has increased/decreased by 0% decreased compared to the previous year.

What impact does a high equity have on investors of EyeGate Pharmaceuticals?

A high equity is advantageous for investors of EyeGate Pharmaceuticals as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of EyeGate Pharmaceuticals?

A low equity can be a risk for investors of EyeGate Pharmaceuticals, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of EyeGate Pharmaceuticals affect the company?

An increase in equity of EyeGate Pharmaceuticals can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of EyeGate Pharmaceuticals affect the company?

A reduction in equity of EyeGate Pharmaceuticals can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of EyeGate Pharmaceuticals?

Some factors that can affect the equity of EyeGate Pharmaceuticals include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of EyeGate Pharmaceuticals so important for investors?

The equity of EyeGate Pharmaceuticals is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can EyeGate Pharmaceuticals take to change the equity?

To change equity, EyeGate Pharmaceuticals can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does EyeGate Pharmaceuticals pay?

Over the past 12 months, EyeGate Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyeGate Pharmaceuticals is expected to pay a dividend of 0.09 USD.

What is the dividend yield of EyeGate Pharmaceuticals?

The current dividend yield of EyeGate Pharmaceuticals is .

When does EyeGate Pharmaceuticals pay dividends?

EyeGate Pharmaceuticals pays a quarterly dividend. This is distributed in the months of July, August, September, October.

How secure is the dividend of EyeGate Pharmaceuticals?

EyeGate Pharmaceuticals paid dividends every year for the past 2 years.

What is the dividend of EyeGate Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0.09 USD are expected. This corresponds to a dividend yield of 0.25 %.

In which sector is EyeGate Pharmaceuticals located?

EyeGate Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von EyeGate Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of EyeGate Pharmaceuticals from 9/6/2024 amounting to 0.149 USD, you needed to have the stock in your portfolio before the ex-date on 9/3/2024.

When did EyeGate Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/6/2024.

What was the dividend of EyeGate Pharmaceuticals in the year 2023?

In the year 2023, EyeGate Pharmaceuticals distributed 0 USD as dividends.

In which currency does EyeGate Pharmaceuticals pay out the dividend?

The dividends of EyeGate Pharmaceuticals are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von EyeGate Pharmaceuticals

Our stock analysis for EyeGate Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyeGate Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.